Cargando…
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
Echinocandins represent the newest class of antifungal agents. Currently, three echinocandins, anidulafungin, caspofungin and micafungin are licensed for clinical use in various indications. They act as inhibitors of β-(1,3)-glucan synthesis in the fungal cell wall and have a favorable pharmacologic...
Autores principales: | Kofla, G, Ruhnke, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352072/ https://www.ncbi.nlm.nih.gov/pubmed/21486730 http://dx.doi.org/10.1186/2047-783X-16-4-159 |
Ejemplares similares
-
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011) -
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011) -
Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
por: Tóth, Zoltán, et al.
Publicado: (2020) -
Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
por: Suh, Jin Woong, et al.
Publicado: (2020) -
Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
por: Marx, Jana, et al.
Publicado: (2020)